{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:04:00Z","timestamp":1793196240424,"version":"4.5.0"},"reference-count":146,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"14","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,5,10]]},"abstract":"\n ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the<\/jats:italic>\n \n ASCO Guidelines Methodology Manual<\/jats:italic>\n <\/jats:ext-link>\n . ASCO Guidelines follow the<\/jats:italic>\n \n ASCO Conflict of Interest Policy for Clinical Practice Guidelines<\/jats:italic>\n <\/jats:ext-link>\n .\n <\/jats:p>\n \n \n Clinical Practice Guidelines and other guidance (\u201cGuidance\u201d) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in\n Appendix 1<\/jats:xref>\n and\n 2<\/jats:xref>\n (online only) for more.\n <\/jats:italic>\n <\/jats:p>\n \n PURPOSE<\/jats:title>\n To update the ASCO evidence-based recommendations on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer treated with initial surgery.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n ASCO convened an Expert Panel to develop updated recommendations based on a systematic literature review (January 2016-May 2024).<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Eleven randomized clinical trials (14 publications), eight meta-analyses and\/or systematic reviews, and one prospective cohort study met the inclusion criteria for this systematic review. Expert Panel members used available evidence and informal consensus to develop practice recommendations.<\/jats:p>\n <\/jats:sec>\n \n RECOMMENDATIONS<\/jats:title>\n Clinicians should not recommend routine SLNB in select patients who are postmenopausal and \u226550 years of age and with negative findings on preoperative axillary ultrasound for grade 1-2, small (\u22642 cm), hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative breast cancer and who undergo breast-conserving therapy. Clinicians may offer postmastectomy radiation (RT) with regional nodal irradiation (RNI) and omit axillary lymph node dissection (ALND) in patients with clinically node-negative invasive breast cancer \u22645 cm who receive mastectomy and have one to two positive sentinel nodes. Clinicians may offer SLNB in patients who have cT3-T4c or multicentric tumors (clinically node-negative) or ductal carcinoma in situ treated with mastectomy, and in patients who are obese, male, or pregnant, or who have had prior breast or axillary surgery. Clinicians should not recommend ALND for patients with early-stage breast cancer who do not have nodal metastases, and clinicians should not recommend ALND for patients with early-stage breast cancer who have one or two sentinel lymph node metastases and will receive breast-conserving surgery and whole-breast RT with or without RNI.<\/jats:p>\n \n Additional information is available at\n www.asco.org\/breast-cancer-guidelines<\/jats:ext-link>\n .\n <\/jats:p>\n This guideline has been endorsed by the American Society for Radiation Oncology (ASTRO).<\/jats:p>\n <\/jats:sec>","DOI":"10.1200\/jco-25-00099","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:59:07Z","timestamp":1744300747000},"page":"1720-1741","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":159,"title":["Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update"],"prefix":"10.1200","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1495-9920","authenticated-orcid":true,"given":"Ko Un","family":"Park","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-0085","authenticated-orcid":true,"given":"Mark R.","family":"Somerfield","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirupama","family":"Anne","sequence":"additional","affiliation":[{"name":"Penn State Health Milton S. Hershey Medical Center, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7741-2199","authenticated-orcid":true,"given":"Muriel","family":"Brackstone","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Western Ontario, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison K.","family":"Conlin","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-4461","authenticated-orcid":true,"given":"Henrique Lima","family":"Couto","sequence":"additional","affiliation":[{"name":"Brazilian Society of Mastology, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn T.","family":"Dengel","sequence":"additional","affiliation":[{"name":"Emily Couric Clinical Cancer Center, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Eisen","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4444-1452","authenticated-orcid":true,"given":"Brittany E.","family":"Harvey","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7009-854X","authenticated-orcid":true,"given":"Jeffrey","family":"Hawley","sequence":"additional","affiliation":[{"name":"Stephanie Spielman Comprehensive Breast Center, The Ohio State University Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-0947","authenticated-orcid":false,"given":"Janice N.","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-0492","authenticated-orcid":true,"given":"Nwamaka","family":"Lasebikan","sequence":"additional","affiliation":[{"name":"University of Nigeria Teaching Hospital, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7209-4216","authenticated-orcid":true,"given":"Elizabeth S.","family":"McDonald","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-275X","authenticated-orcid":true,"given":"Deepti","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Shams","sequence":"additional","affiliation":[{"name":"Piedmont Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-034X","authenticated-orcid":true,"given":"Raymond Mailhot","family":"Vega","sequence":"additional","affiliation":[{"name":"University of Florida, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Dan L. Duncan Comprehensive Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-5216","authenticated-orcid":true,"given":"Mylin A.","family":"Torres","sequence":"additional","affiliation":[{"name":"Glenn Family Breast Center at Winship Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"crossref","first-page":"7703","DOI":"10.1200\/JCO.2005.08.001","article-title":"American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer","volume":"23","author":"Lyman GH","year":"2005","unstructured":"Lyman GH, Giuliano AE, Somerfield MR, et al: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703-7720, 2005","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1200\/JCO.2013.54.1177","article-title":"Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"32","author":"Lyman GH","year":"2014","unstructured":"Lyman GH, Temin S, Edge SB, et al: Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32:1365-1383, 2014","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.2016.71.0947","article-title":"Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Lyman GH","year":"2017","unstructured":"Lyman GH, Somerfield MR, Bosserman LD, et al: Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:561-564, 2017","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.21.00934","article-title":"Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline","volume":"39","author":"Brackstone M","year":"2021","unstructured":"Brackstone M, Baldassarre FG, Perera FE, et al: Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline. J Clin Oncol 39:3056-3082, 2021","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_6_2","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2019","unstructured":"Higgins JPT: Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions (ed 2). Hoboken, NJ, Wiley-Blackwell, 2019","edition":"2"},{"key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem H","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, et al: GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401-406, 2011","journal-title":"J Clin Epidemiol"},{"key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12893-023-02101-8","article-title":"Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: A systematic review and meta-analysis","volume":"23","author":"Fan YJ","year":"2023","unstructured":"Fan YJ, Li JC, Zhu DM, et al: Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: A systematic review and meta-analysis. BMC Surg 23:209, 2023","journal-title":"BMC Surg"},{"key":"e_1_3_9_9_2","first-page":"CD004561","article-title":"Axillary treatment for operable primary breast cancer","volume":"1","author":"Bromham N","year":"2017","unstructured":"Bromham N, Schmidt-Hansen M, Astin M, et al: Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev 1:CD004561, 2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.31557\/APJCP.2022.23.8.2561","article-title":"Comparing early-stage breast cancer patients with sentinel lymph node metastasis with and without completion axillary lymph node dissection: A systematic review and meta-analysis","volume":"23","author":"Heiranizadeh N","year":"2022","unstructured":"Heiranizadeh N, Rafiei Shahamabadi M, Dehghan HR, et al: Comparing early-stage breast cancer patients with sentinel lymph node metastasis with and without completion axillary lymph node dissection: A systematic review and meta-analysis. Asian Pac J Cancer Prev 23:2561-2571, 2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1245\/s10434-020-08225-y","article-title":"Comparing observation, axillary radiotherapy, and completion axillary lymph node dissection for management of axilla in breast cancer in patients with positive sentinel nodes: A systematic review","volume":"27","author":"Castelo M","year":"2020","unstructured":"Castelo M, Hu SY, Dossa F, et al: Comparing observation, axillary radiotherapy, and completion axillary lymph node dissection for management of axilla in breast cancer in patients with positive sentinel nodes: A systematic review. Ann Surg Oncol 27:2664-2676, 2020","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.breast.2021.11.018","article-title":"De-escalating axillary surgery in early-stage breast cancer","volume":"62","author":"Hersh EH","year":"2022","unstructured":"Hersh EH, King TA: De-escalating axillary surgery in early-stage breast cancer. Breast 62:S43-S49, 2022 (suppl 1)","journal-title":"Breast"},{"key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano AE","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al: Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318:918-926, 2017","journal-title":"JAMA"},{"key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","article-title":"Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial","volume":"264","author":"Giuliano AE","year":"2016","unstructured":"Giuliano AE, Ballman K, McCall L, et al: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 264:413-420, 2016","journal-title":"Ann Surg"},{"key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1245\/s10434-016-5177-4","article-title":"Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial","volume":"23","author":"Canavese G","year":"2016","unstructured":"Canavese G, Bruzzi P, Catturich A, et al: Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial. Ann Surg Oncol 23:2494-2500, 2016","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","article-title":"Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial","volume":"43","author":"Savolt A","year":"2017","unstructured":"Savolt A, Peley G, Polgar C, et al: Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol 43:672-679, 2017","journal-title":"Eur J Surg Oncol"},{"key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial","volume":"19","author":"Galimberti V","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, et al: Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 19:1385-1393, 2018","journal-title":"Lancet Oncol"},{"key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-018-4733-y","article-title":"Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial","volume":"170","author":"Roy P","year":"2018","unstructured":"Roy P, Leizorovicz A, Villet R, et al: Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial. Breast Cancer Res Treat 170:303-312, 2018","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","article-title":"Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: The SINODAR-ONE multicenter randomized clinical trial","volume":"29","author":"Tinterri C","year":"2022","unstructured":"Tinterri C, Gentile D, Gatzemeier W, et al: Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: The SINODAR-ONE multicenter randomized clinical trial. Ann Surg Oncol 29:5732-5744, 2022","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.breast.2023.06.009","article-title":"10-year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection","volume":"70","author":"Campbell I","year":"2023","unstructured":"Campbell I, Wetzig N, Ung O, et al: 10-year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection. Breast 70:70-75, 2023","journal-title":"Breast"},{"key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial","volume":"41","author":"Bartels SAL","year":"2023","unstructured":"Bartels SAL, Donker M, Poncet C, et al: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol 41:2159-2165, 2023","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_22_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","article-title":"Omitting axillary dissection in breast cancer with sentinel-node metastases","volume":"390","author":"de Boniface J","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryden L, et al: Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med 390:1163-1175, 2024","journal-title":"N Engl J Med"},{"key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(24)00350-4","article-title":"Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4\/6 inhibitor treatment: A post-hoc analysis of the randomised, phase 3 SENOMAC trial","volume":"25","author":"de Boniface J","year":"2024","unstructured":"de Boniface J, Appelgren M, Szulkin R, et al: Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4\/6 inhibitor treatment: A post-hoc analysis of the randomised, phase 3 SENOMAC trial. Lancet Oncol 25:1222-1230, 2024","journal-title":"Lancet Oncol"},{"key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: The SOUND randomized clinical trial","volume":"9","author":"Gentilini OD","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, et al: Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: The SOUND randomized clinical trial. JAMA Oncol 9:1557-1564, 2023","journal-title":"JAMA Oncol"},{"key":"e_1_3_9_25_2","article-title":"Axillary surgery in breast cancer\u2014primary results of the INSEMA trial","author":"Reimer T","unstructured":"Reimer T, Stachs A, Veselinovic K, et al: Axillary surgery in breast cancer\u2014primary results of the INSEMA trial. N Engl J Med 10.1056\/NEJMoa2412063 [epub ahead of print on December 12, 2024]","journal-title":"N Engl J Med"},{"key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jss.2021.10.006","article-title":"Is axillary assessment of ductal carcinoma in situ of the breast necessary in all cases?","volume":"271","author":"Bellver G","year":"2022","unstructured":"Bellver G, Buch E, Ripoll F, et al: Is axillary assessment of ductal carcinoma in situ of the breast necessary in all cases? J Surg Res 271:145-153, 2022","journal-title":"J Surg Res"},{"key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"101880","DOI":"10.1016\/j.suronc.2022.101880","article-title":"Precise application of sentinel lymph node biopsy in patients with ductal carcinoma in situ: A systematic review and meta-analysis of real-world data","volume":"45","author":"Chiu CW","year":"2022","unstructured":"Chiu CW, Chang LC, Su CM, et al: Precise application of sentinel lymph node biopsy in patients with ductal carcinoma in situ: A systematic review and meta-analysis of real-world data. Surg Oncol 45:101880, 2022","journal-title":"Surg Oncol"},{"key":"e_1_3_9_28_2","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrac022","article-title":"Sentinel lymph node biopsy in patients with ductal carcinoma in situ: Systematic review and meta-analysis","volume":"6","author":"Davey MG","year":"2022","unstructured":"Davey MG, O'Flaherty C, Cleere EF, et al: Sentinel lymph node biopsy in patients with ductal carcinoma in situ: Systematic review and meta-analysis. BJS Open 6, 2022","journal-title":"BJS Open"},{"key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.amjsurg.2016.04.019","article-title":"Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis","volume":"213","author":"El Hage Chehade H","year":"2017","unstructured":"El Hage Chehade H, Headon H, Wazir U, et al: Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis. Am J Surg 213:171-180, 2017","journal-title":"Am J Surg"},{"key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"e14134","DOI":"10.1111\/eci.14134","article-title":"Sentinel lymph node biopsy for breast cancer during pregnancy: A comprehensive update","volume":"54","author":"Bothou A","year":"2024","unstructured":"Bothou A, Margioula-Siarkou C, Petousis S, et al: Sentinel lymph node biopsy for breast cancer during pregnancy: A comprehensive update. Eur J Clin Invest 54:e14134, 2024","journal-title":"Eur J Clin Invest"},{"key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"101756","DOI":"10.1016\/j.eclinm.2022.101756","article-title":"Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer","volume":"55","author":"Reimer T","year":"2023","unstructured":"Reimer T, Stachs A, Veselinovic K, et al: Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine 55:101756, 2023","journal-title":"EClinicalMedicine"},{"key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"653388","DOI":"10.3389\/fonc.2021.653388","article-title":"Clinical relevance of tubular breast carcinoma: Large retrospective study and meta-analysis","volume":"11","author":"Metovic J","year":"2021","unstructured":"Metovic J, Bragoni A, Osella-Abate S, et al: Clinical relevance of tubular breast carcinoma: Large retrospective study and meta-analysis. Front Oncol 11:653388, 2021","journal-title":"Front Oncol"},{"key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1200\/JCO.2006.08.8013","article-title":"Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation","volume":"25","author":"Bevilacqua JL","year":"2007","unstructured":"Bevilacqua JL, Kattan MW, Fey JV, et al: Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol 25:3670-3679, 2007","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0360-3016(00)00605-2","article-title":"The relationship between lymphatic vessell invasion, tumor size, and pathologic nodal status: Can we predict who can avoid a third field in the absence of axillary dissection?","volume":"48","author":"Wong JS","year":"2000","unstructured":"Wong JS, O'Neill A, Recht A, et al: The relationship between lymphatic vessell invasion, tumor size, and pathologic nodal status: Can we predict who can avoid a third field in the absence of axillary dissection? Int J Radiat Oncol Biol Phys 48:133-137, 2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<948::AID-CNCR21>3.0.CO;2-U","article-title":"Prediction of axillary lymph node involvement of women with invasive breast carcinoma: A multivariate analysis","volume":"83","author":"Olivotto IA","year":"1998","unstructured":"Olivotto IA, Jackson JS, Mates D, et al: Prediction of axillary lymph node involvement of women with invasive breast carcinoma: A multivariate analysis. Cancer 83:948-955, 1998","journal-title":"Cancer"},{"key":"e_1_3_9_36_2","volume-title":"Breast Cancer Nomogram to Predict Positive Sentinel Lymph Nodes, Without Neoadjuvant Chemotherapy","author":"MD Anderson Cancer Center","year":"2024","unstructured":"MD Anderson Cancer Center: Breast Cancer Nomogram to Predict Positive Sentinel Lymph Nodes, Without Neoadjuvant Chemotherapy. 2024. https:\/\/www3.mdanderson.org\/app\/medcalc\/bc_nomogram3\/index.cfm?pagename=sln"},{"key":"e_1_3_9_37_2","volume-title":"Breast Cancer Nomogram: Sentinel Lymph Node Metastasis","author":"Memorial Sloan Kettering Cancer Center","year":"2024","unstructured":"Memorial Sloan Kettering Cancer Center: Breast Cancer Nomogram: Sentinel Lymph Node Metastasis, 2024. https:\/\/nomograms.mskcc.org\/Breast\/BreastSLNodeMetastasisPage.aspx"},{"key":"e_1_3_9_38_2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.breast.2012.06.013","article-title":"Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND)","volume":"21","author":"Gentilini O","year":"2012","unstructured":"Gentilini O, Veronesi U: Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast 21:678-681, 2012","journal-title":"Breast"},{"key":"e_1_3_9_39_2","doi-asserted-by":"crossref","first-page":"20180929","DOI":"10.1259\/bjr.20180929","article-title":"Contrast enhanced digital mammography versus magnetic resonance imaging for accurate measurement of the size of breast cancer","volume":"92","author":"Youn I","year":"2019","unstructured":"Youn I, Choi S, Choi YJ, et al: Contrast enhanced digital mammography versus magnetic resonance imaging for accurate measurement of the size of breast cancer. Br J Radiol 92:20180929, 2019","journal-title":"Br J Radiol"},{"key":"e_1_3_9_40_2","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/j.clbc.2016.07.007","article-title":"The accuracy of breast MR imaging for measuring the size of a breast cancer: Analysis of the histopathologic factors","volume":"16","author":"Choi WJ","year":"2016","unstructured":"Choi WJ, Cha JH, Kim HH, et al: The accuracy of breast MR imaging for measuring the size of a breast cancer: Analysis of the histopathologic factors. Clin Breast Cancer 16:e145-e152, 2016","journal-title":"Clin Breast Cancer"},{"key":"e_1_3_9_41_2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ejso.2020.04.038","article-title":"Reliability of MRI tumor size measurements for minimal invasive treatment selection in small breast cancers","volume":"46","author":"Sanderink WBG","year":"2020","unstructured":"Sanderink WBG, Caballo M, Strobbe LJA, et al: Reliability of MRI tumor size measurements for minimal invasive treatment selection in small breast cancers. Eur J Surg Oncol 46:1463-1470, 2020","journal-title":"Eur J Surg Oncol"},{"key":"e_1_3_9_42_2","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1245\/s10434-012-2289-3","article-title":"Limited value and utility of breast MRI in patients undergoing breast-conserving cancer surgery","volume":"19","author":"Shin HC","year":"2012","unstructured":"Shin HC, Han W, Moon HG, et al: Limited value and utility of breast MRI in patients undergoing breast-conserving cancer surgery. Ann Surg Oncol 19:2572-2579, 2012","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_43_2","volume-title":"MRI Exam-Specific Parameters","author":"American College of Radiology","year":"2024","unstructured":"American College of Radiology: MRI Exam-Specific Parameters. Breast, 2024. https:\/\/accreditationsupport.acr.org\/support\/solutions\/articles\/11000114407-mri-exam-specific-parameters-breast-revised-5-2-2024"},{"key":"e_1_3_9_44_2","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1245\/s10434-011-2200-7","article-title":"Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging","volume":"19","author":"Valente SA","year":"2012","unstructured":"Valente SA, Levine GM, Silverstein MJ, et al: Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging. Ann Surg Oncol 19:1825-1830, 2012","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_45_2","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343","volume":"31","author":"Hughes KS","year":"2013","unstructured":"Hughes KS, Schnaper LA, Bellon JR, et al: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J Clin Oncol 31:2382-2387, 2013","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_46_2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/cncr.28499","article-title":"Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09\/98)","volume":"120","author":"Agresti R","year":"2014","unstructured":"Agresti R, Martelli G, Sandri M, et al: Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09\/98). Cancer 120:885-893, 2014","journal-title":"Cancer"},{"key":"e_1_3_9_47_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000167759.15670.14","article-title":"A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: Results after 5 years of follow-up","volume":"242","author":"Martelli G","year":"2005","unstructured":"Martelli G, Boracchi P, De Palo M, et al: A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: Results after 5 years of follow-up. Ann Surg 242:1-6, 2005; discussion 7-9","journal-title":"Ann Surg"},{"key":"e_1_3_9_48_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ejso.2014.03.029","article-title":"Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-year results of trial and out-trial patients","volume":"40","author":"Martelli G","year":"2014","unstructured":"Martelli G, Boracchi P, Orenti A, et al: Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-year results of trial and out-trial patients. Eur J Surg Oncol 40:805-812, 2014","journal-title":"Eur J Surg Oncol"},{"key":"e_1_3_9_49_2","volume-title":"Five Things Physicians and Patients Should Question","author":"Society of Surgical Oncology: Choosing, Wisely","year":"2020","unstructured":"Society of Surgical Oncology: Choosing, Wisely: Five Things Physicians and Patients Should Question, 2020. https:\/\/www.surgonc.org\/wp-content\/uploads\/2024\/04\/FINAL_Choosing_Wisely_5.30.23-SSO-5things-List_2021-Updates.pdf"},{"key":"e_1_3_9_50_2","first-page":"703160","article-title":"Ultrasound guided core biopsy versus fine needle aspiration for evaluation of axillary lymphadenopathy in patients with breast cancer","volume":"2014","author":"Ganott MA","year":"2014","unstructured":"Ganott MA, Zuley ML, Abrams GS, et al: Ultrasound guided core biopsy versus fine needle aspiration for evaluation of axillary lymphadenopathy in patients with breast cancer. ISRN Oncol 2014:703160, 2014","journal-title":"ISRN Oncol"},{"key":"e_1_3_9_51_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/SLA.0b013e31821f1564","article-title":"Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla","volume":"254","author":"Houssami N","year":"2011","unstructured":"Houssami N, Ciatto S, Turner RM, et al: Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg 254:243-251, 2011","journal-title":"Ann Surg"},{"key":"e_1_3_9_52_2","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.jacr.2024.02.021","article-title":"ACR Appropriateness Criteria\u00ae imaging of invasive breast cancer","volume":"21","author":"Expert Panel on Breast Imaging","year":"2024","unstructured":"Expert Panel on Breast Imaging; McDonald ES, Scheel JR, et al: ACR Appropriateness Criteria\u00ae imaging of invasive breast cancer. J Am Coll Radiol 21:S168-S202, 2024","journal-title":"J Am Coll Radiol"},{"key":"e_1_3_9_53_2","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1245\/s10434-009-0421-9","article-title":"Axillary staging by percutaneous biopsy: Sensitivity of fine-needle aspiration versus core needle biopsy","volume":"16","author":"Rao R","year":"2009","unstructured":"Rao R, Lilley L, Andrews V, et al: Axillary staging by percutaneous biopsy: Sensitivity of fine-needle aspiration versus core needle biopsy. Ann Surg Oncol 16:1170-1175, 2009","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_54_2","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/bjs.10920","article-title":"Meta-analysis of the diagnostic accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis","volume":"105","author":"Balasubramanian I","year":"2018","unstructured":"Balasubramanian I, Fleming CA, Corrigan MA, et al: Meta-analysis of the diagnostic accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis. Br J Surg 105:1244-1253, 2018","journal-title":"Br J Surg"},{"key":"e_1_3_9_55_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.crad.2016.02.024","article-title":"A randomised pilot study comparing 13 G vacuum-assisted biopsy and conventional 14 G core needle biopsy of axillary lymph nodes in women with breast cancer","volume":"71","author":"Maxwell AJ","year":"2016","unstructured":"Maxwell AJ, Bundred NJ, Harvey J, et al: A randomised pilot study comparing 13 G vacuum-assisted biopsy and conventional 14 G core needle biopsy of axillary lymph nodes in women with breast cancer. Clin Radiol 71:551-557, 2016","journal-title":"Clin Radiol"},{"key":"e_1_3_9_56_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","article-title":"Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: An ASTRO clinical practice guideline","volume":"14","author":"Shaitelman SF","year":"2024","unstructured":"Shaitelman SF, Anderson BM, Arthur DW, et al: Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: An ASTRO clinical practice guideline. Pract Radiat Oncol 14:112-132, 2024","journal-title":"Pract Radiat Oncol"},{"key":"e_1_3_9_57_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2207586","article-title":"Breast-conserving surgery with or without irradiation in early breast cancer","volume":"388","author":"Kunkler IH","year":"2023","unstructured":"Kunkler IH, Williams LJ, Jack WJL, et al: Breast-conserving surgery with or without irradiation in early breast cancer. N Engl J Med 388:585-594, 2023","journal-title":"N Engl J Med"},{"key":"e_1_3_9_58_2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","article-title":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"390","author":"Coles CE","year":"2017","unstructured":"Coles CE, Griffin CL, Kirby AM, et al: Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390:1048-1060, 2017","journal-title":"Lancet"},{"key":"e_1_3_9_59_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1200\/JCO.18.00982","article-title":"Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: Longitudinal analysis of the IMPORT LOW (CRUK\/06\/003) phase III randomized controlled trial","volume":"37","author":"Bhattacharya IS","year":"2019","unstructured":"Bhattacharya IS, Haviland JS, Kirby AM, et al: Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: Longitudinal analysis of the IMPORT LOW (CRUK\/06\/003) phase III randomized controlled trial. J Clin Oncol 37:305-317, 2019","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_60_2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ijrobp.2023.10.016","article-title":"Accelerated partial breast irradiation using 5 daily fractions: A prospective, phase 2, multicenter trial of cosmetic outcomes and toxicity-ACCEL final results","volume":"118","author":"Grendarova P","year":"2024","unstructured":"Grendarova P, Roumeliotis M, Quirk S, et al: Accelerated partial breast irradiation using 5 daily fractions: A prospective, phase 2, multicenter trial of cosmetic outcomes and toxicity-ACCEL final results. Int J Radiat Oncol Biol Phys 118:1041-1048, 2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_9_61_2","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1200\/JCO.20.00650","article-title":"Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: Long-term results of the randomized phase III APBI-IMRT-florence trial","volume":"38","author":"Meattini I","year":"2020","unstructured":"Meattini I, Marrazzo L, Saieva C, et al: Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: Long-term results of the randomized phase III APBI-IMRT-florence trial. J Clin Oncol 38:4175-4183, 2020","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_62_2","doi-asserted-by":"crossref","first-page":"8624","DOI":"10.1245\/s10434-021-10173-0","article-title":"Subclinical lymphedema after treatment for breast cancer: Risk of progression and considerations for early intervention","volume":"28","author":"Bucci LK","year":"2021","unstructured":"Bucci LK, Brunelle CL, Bernstein MC, et al: Subclinical lymphedema after treatment for breast cancer: Risk of progression and considerations for early intervention. Ann Surg Oncol 28:8624-8633, 2021","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_63_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","article-title":"Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"8","author":"Smith BD","year":"2018","unstructured":"Smith BD, Bellon JR, Blitzblau R, et al: Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 8:145-152, 2018","journal-title":"Pract Radiat Oncol"},{"key":"e_1_3_9_64_2","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: A randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt AM","year":"2020","unstructured":"Brunt AM, Haviland JS, Sydenham M, et al: Ten-year results of FAST: A randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 38:3261-3272, 2020","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_65_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1470-2045(24)00661-2","article-title":"Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): A preplanned interim analysis of a phase 3, non-inferiority, randomised trial","volume":"26","author":"Meattini I","year":"2025","unstructured":"Meattini I, De Santis MC, Visani L, et al: Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): A preplanned interim analysis of a phase 3, non-inferiority, randomised trial. Lancet Oncol 26:37-50, 2025","journal-title":"Lancet Oncol"},{"key":"e_1_3_9_66_2","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky K","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al: 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385:2336-2347, 2021","journal-title":"N Engl J Med"},{"key":"e_1_3_9_67_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano JA","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111-121, 2018","journal-title":"N Engl J Med"},{"key":"e_1_3_9_68_2","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano JA","year":"2019","unstructured":"Sparano JA, Gray RJ, Ravdin PM, et al: Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 380:2395-2405, 2019","journal-title":"N Engl J Med"},{"key":"e_1_3_9_69_2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre F","year":"2022","unstructured":"Andre F, Ismaila N, Allison KH, et al: Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol 40:1816-1837, 2022","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_70_2","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.24.00886","article-title":"Optimal adjuvant chemotherapy and targeted therapy for early breast cancer-cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update","volume":"42","author":"Freedman RA","year":"2024","unstructured":"Freedman RA, Caswell-Jin JL, Hassett M, et al: Optimal adjuvant chemotherapy and targeted therapy for early breast cancer-cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update. J Clin Oncol 42:2233-2235, 2024","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_71_2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon D","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, et al: Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med 390:1080-1091, 2024","journal-title":"N Engl J Med"},{"key":"e_1_3_9_72_2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","article-title":"Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial","volume":"252","author":"Giuliano AE","year":"2010","unstructured":"Giuliano AE, McCall L, Beitsch P, et al: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426-432, 2010; discussion 432-433","journal-title":"Ann Surg"},{"key":"e_1_3_9_73_2","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2014.56.5838","article-title":"Radiation field design in the ACOSOG Z0011 (Alliance) trial","volume":"32","author":"Jagsi R","year":"2014","unstructured":"Jagsi R, Chadha M, Moni J, et al: Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin Oncol 32:3600-3606, 2014","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_74_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1415340","article-title":"Regional nodal irradiation in early-stage breast cancer","volume":"373","author":"Whelan TJ","year":"2015","unstructured":"Whelan TJ, Olivotto IA, Parulekar WR, et al: Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373:307-316, 2015","journal-title":"N Engl J Med"},{"key":"e_1_3_9_75_2","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","article-title":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial","volume":"21","author":"Poortmans PM","year":"2020","unstructured":"Poortmans PM, Weltens C, Fortpied C, et al: Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol 21:1602-1610, 2020","journal-title":"Lancet Oncol"},{"key":"e_1_3_9_76_2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/bjs\/znad215","article-title":"Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: Sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment","volume":"110","author":"Tinterri C","year":"2023","unstructured":"Tinterri C, Canavese G, Gatzemeier W, et al: Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: Sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. Br J Surg 110:1143-1152, 2023","journal-title":"Br J Surg"},{"key":"e_1_3_9_77_2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker M","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303-1310, 2014","journal-title":"Lancet Oncol"},{"key":"e_1_3_9_78_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton DL","year":"1992","unstructured":"Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392-399, 1992","journal-title":"Arch Surg"},{"key":"e_1_3_9_79_2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJM199810013391401","article-title":"The sentinel node in breast cancer--a multicenter validation study","volume":"339","author":"Krag D","year":"1998","unstructured":"Krag D, Weaver D, Ashikaga T, et al: The sentinel node in breast cancer--a multicenter validation study. N Engl J Med 339:941-946, 1998","journal-title":"N Engl J Med"},{"key":"e_1_3_9_80_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00000658-199409000-00015","article-title":"Lymphatic mapping and sentinel lymphadenectomy for breast cancer","volume":"220","author":"Giuliano AE","year":"1994","unstructured":"Giuliano AE, Kirgan DM, Guenther JM, et al: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391-398, 1994; discussion 398-401","journal-title":"Ann Surg"},{"key":"e_1_3_9_81_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa012782","article-title":"A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer","volume":"349","author":"Veronesi U","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G, et al: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546-553, 2003","journal-title":"N Engl J Med"},{"key":"e_1_3_9_82_2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag DN","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al: Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927-933, 2010","journal-title":"Lancet Oncol"},{"key":"e_1_3_9_83_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2011.1034","article-title":"Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer","volume":"306","author":"Giuliano AE","year":"2011","unstructured":"Giuliano AE, Hawes D, Ballman KV, et al: Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 306:385-393, 2011","journal-title":"JAMA"},{"key":"e_1_3_9_84_2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1008108","article-title":"Effect of occult metastases on survival in node-negative breast cancer","volume":"364","author":"Weaver DL","year":"2011","unstructured":"Weaver DL, Ashikaga T, Krag DN, et al: Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 364:412-421, 2011","journal-title":"N Engl J Med"},{"key":"e_1_3_9_85_2","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1200\/JCO.22.02553","article-title":"Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: Results from ACOSOG Z11102 (Alliance)","volume":"41","author":"Boughey JC","year":"2023","unstructured":"Boughey JC, Rosenkranz KM, Ballman KV, et al: Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: Results from ACOSOG Z11102 (Alliance). J Clin Oncol 41:3184-3193, 2023","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_86_2","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1245\/s10434-022-12099-7","article-title":"Overuse of axillary surgery in patients with ductal carcinoma in situ: Opportunity for de-escalation","volume":"29","author":"Piltin MA","year":"2022","unstructured":"Piltin MA, Hoskin TL, Day CN, et al: Overuse of axillary surgery in patients with ductal carcinoma in situ: Opportunity for de-escalation. Ann Surg Oncol 29:7705-7712, 2022","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_87_2","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.clbc.2016.10.002","article-title":"Sentinel node procedure obsolete in lumpectomy for ductal carcinoma in situ","volume":"17","author":"Heymans C","year":"2017","unstructured":"Heymans C, van Bastelaar J, Visschers RGJ, et al: Sentinel node procedure obsolete in lumpectomy for ductal carcinoma in situ. Clin Breast Cancer 17:e87-e93, 2017","journal-title":"Clin Breast Cancer"},{"key":"e_1_3_9_88_2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/ans.18936","article-title":"Avoiding unnecessary sentinel lymph node biopsy with the use of superparamagnetic iron oxide mapping agents (Magtrace\u00ae) in breast surgery","volume":"94","author":"Cui RBJ","year":"2024","unstructured":"Cui RBJ, Hawes S, Azimi F, et al: Avoiding unnecessary sentinel lymph node biopsy with the use of superparamagnetic iron oxide mapping agents (Magtrace\u00ae) in breast surgery. ANZ J Surg 94:1090-1095, 2024","journal-title":"ANZ J Surg"},{"key":"e_1_3_9_89_2","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1245\/s10434-022-13064-0","article-title":"Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: The SentiNot study","volume":"30","author":"Karakatsanis A","year":"2023","unstructured":"Karakatsanis A, Eriksson S, Pistiolis L, et al: Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: The SentiNot study. Ann Surg Oncol 30:4064-4072, 2023","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_90_2","doi-asserted-by":"publisher","unstructured":"Samaha M Fellner A Raque K et al: Magnetic lymphatic tracing for omission of sentinel lymph node biopsies in mastectomy patients: A community cancer center experience. Breast Cancer Res Treat 10.1007\/s10549-024-07482-9 [epub ahead of print on September 24 2024]","DOI":"10.1007\/s10549-024-07482-9"},{"key":"e_1_3_9_91_2","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1245\/s10434-018-6384-y","article-title":"Risk of regional recurrence after negative repeat sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence","volume":"25","author":"Poodt IGM","year":"2018","unstructured":"Poodt IGM, Vugts G, Maaskant-Braat AJG, et al: Risk of regional recurrence after negative repeat sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence. Ann Surg Oncol 25:1312-1321, 2018","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_92_2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1245\/s10434-018-6358-0","article-title":"Repeat sentinel lymph node biopsy for ipsilateral breast tumor recurrence: A systematic review of the results and impact on prognosis","volume":"25","author":"Poodt IGM","year":"2018","unstructured":"Poodt IGM, Vugts G, Schipper RJ, et al: Repeat sentinel lymph node biopsy for ipsilateral breast tumor recurrence: A systematic review of the results and impact on prognosis. Ann Surg Oncol 25:1329-1339, 2018","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_93_2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00404-021-06352-9","article-title":"Prognostic value and management of regional lymph nodes in locoregional breast cancer recurrence: A systematic review of the literature","volume":"306","author":"Ge I","year":"2022","unstructured":"Ge I, Erbes T, Juhasz-Boss I: Prognostic value and management of regional lymph nodes in locoregional breast cancer recurrence: A systematic review of the literature. Arch Gynecol Obstet 306:943-957, 2022","journal-title":"Arch Gynecol Obstet"},{"key":"e_1_3_9_94_2","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1200\/JCO.2008.17.4862","article-title":"Internal mammary nodes in breast cancer: Diagnosis and implications for patient management\u2014a systematic review","volume":"26","author":"Chen RC","year":"2008","unstructured":"Chen RC, Lin NU, Golshan M, et al: Internal mammary nodes in breast cancer: Diagnosis and implications for patient management\u2014a systematic review. J Clin Oncol 26:4981-4989, 2008","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_95_2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0959-8049(99)00133-1","article-title":"The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial","volume":"35","author":"Veronesi U","year":"1999","unstructured":"Veronesi U, Marubini E, Mariani L, et al: The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer 35:1320-1325, 1999","journal-title":"Eur J Cancer"},{"key":"e_1_3_9_96_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/tbcr-24-2","article-title":"Internal mammary lymphadenopathy in breast cancer: A narrative review and update","volume":"5","author":"Eckert KM","year":"2024","unstructured":"Eckert KM, Boughey JC, Piltin MA: Internal mammary lymphadenopathy in breast cancer: A narrative review and update. Transl Breast Cancer Res 5:11, 2024","journal-title":"Transl Breast Cancer Res"},{"key":"e_1_3_9_97_2","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1245\/s10434-024-15708-9","article-title":"Internal mammary lymphadenopathy does not impact oncologic outcomes in patients treated with neoadjuvant chemotherapy: Results from the I-SPY2 Clinical Trial","volume":"31","author":"Piltin MA","year":"2024","unstructured":"Piltin MA, Norwood P, Ladores V, et al: Internal mammary lymphadenopathy does not impact oncologic outcomes in patients treated with neoadjuvant chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol 31:7420-7428, 2024","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_98_2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamasurg.2020.0322","article-title":"Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: A systematic review","volume":"155","author":"Wang T","year":"2020","unstructured":"Wang T, Baskin AS, Dossett LA: Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: A systematic review. JAMA Surg 155:759-770, 2020","journal-title":"JAMA Surg"},{"key":"e_1_3_9_99_2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.amjsurg.2017.07.036","article-title":"Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?","volume":"214","author":"Chagpar AB","year":"2017","unstructured":"Chagpar AB, Horowitz N, Sanft T, et al: Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer? Am J Surg 214:1082-1088, 2017","journal-title":"Am J Surg"},{"key":"e_1_3_9_100_2","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1245\/s10434-017-6013-1","article-title":"Surgeon and radiation oncologist views on omission of adjuvant radiotherapy for older women with early-stage breast cancer","volume":"24","author":"Shumway DA","year":"2017","unstructured":"Shumway DA, Griffith KA, Sabel MS, et al: Surgeon and radiation oncologist views on omission of adjuvant radiotherapy for older women with early-stage breast cancer. Ann Surg Oncol 24:3518-3526, 2017","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_101_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10549-020-05579-5","article-title":"Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care?","volume":"180","author":"Taylor LJ","year":"2020","unstructured":"Taylor LJ, Steiman JS, Anderson B, et al: Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care? Breast Cancer Res Treat 180:801-807, 2020","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_9_102_2","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.prro.2014.12.003","article-title":"Patterns of care for omission of radiation therapy for elderly women with early-stage breast cancer receiving hormonal therapy","volume":"5","author":"Rhieu BH","year":"2015","unstructured":"Rhieu BH, Rajagopalan MS, Sukumvanich P, et al: Patterns of care for omission of radiation therapy for elderly women with early-stage breast cancer receiving hormonal therapy. Pract Radiat Oncol 5:e267-e273, 2015","journal-title":"Pract Radiat Oncol"},{"key":"e_1_3_9_103_2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/cncr.32668","article-title":"Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer","volume":"126","author":"Downs-Canner SM","year":"2020","unstructured":"Downs-Canner SM, Gaber CE, Louie RJ, et al: Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer. Cancer 126:1193-1201, 2020","journal-title":"Cancer"},{"key":"e_1_3_9_104_2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1245\/s10434-020-08823-w","article-title":"Trends in breast cancer treatment de-implementation in older patients with hormone receptor-positive breast cancer: A mixed methods study","volume":"28","author":"Wang T","year":"2021","unstructured":"Wang T, Baskin A, Miller J, et al: Trends in breast cancer treatment de-implementation in older patients with hormone receptor-positive breast cancer: A mixed methods study. Ann Surg Oncol 28:902-913, 2021","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_9_105_2","doi-asserted-by":"crossref","first-page":"e2228524","DOI":"10.1001\/jamanetworkopen.2022.28524","article-title":"Assessment of oncologists' perspectives on omission of sentinel lymph node biopsy in women 70 years and older with early-stage hormone receptor-positive breast cancer","volume":"5","author":"Minami CA","year":"2022","unstructured":"Minami CA, Bryan AF, Freedman RA, et al: Assessment of oncologists' perspectives on omission of sentinel lymph node biopsy in women 70 years and older with early-stage hormone receptor-positive breast cancer. JAMA Netw Open 5:e2228524, 2022","journal-title":"JAMA Netw Open"},{"key":"e_1_3_9_106_2","doi-asserted-by":"crossref","first-page":"e2017129","DOI":"10.1001\/jamanetworkopen.2020.17129","article-title":"Patient perspectives on treatment options for older women with hormone receptor-positive breast cancer: A qualitative study","volume":"3","author":"Wang T","year":"2020","unstructured":"Wang T, Mott N, Miller J, et al: Patient perspectives on treatment options for older women with hormone receptor-positive breast cancer: A qualitative study. JAMA Netw Open 3:e2017129, 2020","journal-title":"JAMA Netw Open"},{"key":"e_1_3_9_107_2","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2017.75.2311","article-title":"Patient-clinician communication: American Society of Clinical Oncology consensus guideline","volume":"35","author":"Gilligan T","year":"2017","unstructured":"Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. J Clin Oncol 35:3618-3632, 2017","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_108_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1200\/OP.23.00810","article-title":"Social determinants of health and cancer care: An ASCO policy statement","volume":"20","author":"Tucker-Seeley R","year":"2024","unstructured":"Tucker-Seeley R, Abu-Khalaf M, Bona K, et al: Social determinants of health and cancer care: An ASCO policy statement. JCO Oncol Pract 20:621-630, 2024","journal-title":"JCO Oncol Pract"},{"key":"e_1_3_9_109_2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1200\/JCO.21.02004","article-title":"Linking structural racism and discrimination and breast cancer outcomes: A social genomics approach","volume":"40","author":"Carlos RC","year":"2022","unstructured":"Carlos RC, Obeng-Gyasi S, Cole SW, et al: Linking structural racism and discrimination and breast cancer outcomes: A social genomics approach. J Clin Oncol 40:1407-1413, 2022","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_110_2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jamasurg.2014.23","article-title":"Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer","volume":"149","author":"Black DM","year":"2014","unstructured":"Black DM, Jiang J, Kuerer HM, et al: Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg 149:788-796, 2014","journal-title":"JAMA Surg"},{"key":"e_1_3_9_111_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10549-018-4881-0","article-title":"Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: Analysis of the national cancer database","volume":"172","author":"Parekh A","year":"2018","unstructured":"Parekh A, Fu W, Hu C, et al: Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: Analysis of the national cancer database. Breast Cancer Res Treat 172:201-208, 2018","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_9_112_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/COC.0000000000000094","article-title":"Trend in age and racial disparities in the receipt of postlumpectomy radiation therapy for stage I breast cancer: 2004-2009","volume":"39","author":"Yeboa DN","year":"2016","unstructured":"Yeboa DN, Xu X, Jones BA, et al: Trend in age and racial disparities in the receipt of postlumpectomy radiation therapy for stage I breast cancer: 2004-2009. Am J Clin Oncol 39:568-574, 2016","journal-title":"Am J Clin Oncol"},{"key":"e_1_3_9_113_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijrobp.2022.03.007","article-title":"Evaluating regional nodal irradiation allocation and association with oncologic outcomes in NSABP B-18, B-27, B-40, and B-41","volume":"113","author":"Mailhot VegaRB","year":"2022","unstructured":"Mailhot VegaRB, Wang S, Brooks ED, et al: Evaluating regional nodal irradiation allocation and association with oncologic outcomes in NSABP B-18, B-27, B-40, and B-41. Int J Radiat Oncol Biol Phys 113:542-551, 2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_9_114_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10549-023-06941-z","article-title":"Racial\/ethnic and socioeconomic differences in breast cancer surgery performed and delayed treatment: Mediating impact on mortality","volume":"199","author":"Fwelo P","year":"2023","unstructured":"Fwelo P, Nwosu KOS, Adekunle TE, et al: Racial\/ethnic and socioeconomic differences in breast cancer surgery performed and delayed treatment: Mediating impact on mortality. Breast Cancer Res Treat 199:511-531, 2023","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_9_115_2","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.7314\/APJCP.2013.14.12.7133","article-title":"Assessing the impact of socio-economic variables on breast cancer treatment outcome disparity","volume":"14","author":"Cheung MR","year":"2013","unstructured":"Cheung MR: Assessing the impact of socio-economic variables on breast cancer treatment outcome disparity. Asian Pac J Cancer Prev 14:7133-7136, 2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_3_9_116_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-017-4300-y","article-title":"Influence of clinical, societal, and treatment variables on racial differences in ER-\/PR- breast cancer survival","volume":"165","author":"Roseland ME","year":"2017","unstructured":"Roseland ME, Schwartz K, Ruterbusch JJ, et al: Influence of clinical, societal, and treatment variables on racial differences in ER-\/PR- breast cancer survival. Breast Cancer Res Treat 165:163-168, 2017","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_9_117_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2023.4837","article-title":"Global stage distribution of breast cancer at diagnosis: A systematic review and meta-analysis","volume":"10","author":"Benitez Fuentes JD","year":"2024","unstructured":"Benitez Fuentes JD, Morgan E, de Luna Aguilar A, et al: Global stage distribution of breast cancer at diagnosis: A systematic review and meta-analysis. JAMA Oncol 10:71-78, 2024","journal-title":"JAMA Oncol"},{"key":"e_1_3_9_118_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(11)70031-6","article-title":"Optimisation of breast cancer management in low-resource and middle-resource countries: Executive summary of the Breast Health Global Initiative consensus, 2010","volume":"12","author":"Anderson BO","year":"2011","unstructured":"Anderson BO, Cazap E, El Saghir NS, et al: Optimisation of breast cancer management in low-resource and middle-resource countries: Executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol 12:387-398, 2011","journal-title":"Lancet Oncol"},{"key":"e_1_3_9_119_2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani C","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, et al: Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023-1075, 2018","journal-title":"Lancet"},{"key":"e_1_3_9_120_2","article-title":"COVID-19 and breast cancer diagnosis in Brazil: An analogy to the sinking of the titanic","author":"Freitas-Junior R","unstructured":"Freitas-Junior R, Rocha A, Couto HL, et al: COVID-19 and breast cancer diagnosis in Brazil: An analogy to the sinking of the titanic. JCO Glob Oncol 10.1200\/GO.23.00108","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_9_121_2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0140-6736(22)00184-2","article-title":"The Lancet Breast Cancer Commission: Tackling a global health, gender, and equity challenge","volume":"399","author":"Coles CE","year":"2022","unstructured":"Coles CE, Anderson BO, Cameron D, et al: The Lancet Breast Cancer Commission: Tackling a global health, gender, and equity challenge. Lancet 399:1101-1103, 2022","journal-title":"Lancet"},{"key":"e_1_3_9_122_2","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(24)00747-5","article-title":"The Lancet Breast Cancer Commission","volume":"403","author":"Coles CE","year":"2024","unstructured":"Coles CE, Earl H, Anderson BO, et al: The Lancet Breast Cancer Commission. Lancet 403:1895-1950, 2024","journal-title":"Lancet"},{"key":"e_1_3_9_123_2","first-page":"e3071","article-title":"Impact of delayed adjuvant radiotherapy in the survival of women with breast cancer","volume":"10","author":"Flores-Balcazar CH","year":"2018","unstructured":"Flores-Balcazar CH, Flores-Luna L, Villarreal-Garza C, et al: Impact of delayed adjuvant radiotherapy in the survival of women with breast cancer. Cureus 10:e3071, 2018","journal-title":"Cureus"},{"key":"e_1_3_9_124_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.clon.2016.07.010","article-title":"The effect of waiting times for postoperative radiotherapy on outcomes for women receiving partial mastectomy for breast cancer: A systematic review and meta-analysis","volume":"28","author":"Gupta S","year":"2016","unstructured":"Gupta S, King WD, Korzeniowski M, et al: The effect of waiting times for postoperative radiotherapy on outcomes for women receiving partial mastectomy for breast cancer: A systematic review and meta-analysis. Clin Oncol (R Coll Radiol) 28:739-749, 2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"e_1_3_9_125_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.2003.04.171","article-title":"Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review","volume":"21","author":"Huang J","year":"2003","unstructured":"Huang J, Barbera L, Brouwers M, et al: Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 21:555-563, 2003","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_126_2","first-page":"701","article-title":"Patients' barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator","volume":"103","author":"Hendren S","year":"2011","unstructured":"Hendren S, Chin N, Fisher S, et al: Patients' barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc 103:701-710, 2011","journal-title":"J Natl Med Assoc"},{"key":"e_1_3_9_127_2","first-page":"1","article-title":"Gender- and sexual orientation- based inequities: Promoting inclusion, visibility, and data accuracy in oncology","volume":"42","author":"Alpert AB","year":"2022","unstructured":"Alpert AB, Scout NFN, Schabath MB, et al: Gender- and sexual orientation- based inequities: Promoting inclusion, visibility, and data accuracy in oncology. Am Soc Clin Oncol Educ Book 42:1-17, 2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_9_128_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/OP.20.00174","article-title":"Closing the rural cancer care gap: Three institutional approaches","volume":"16","author":"Levit LA","year":"2020","unstructured":"Levit LA, Byatt L, Lyss AP, et al: Closing the rural cancer care gap: Three institutional approaches. JCO Oncol Pract 16:422-430, 2020","journal-title":"JCO Oncol Pract"},{"key":"e_1_3_9_129_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10549-020-05768-2","article-title":"Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound","volume":"183","author":"McEvoy AM","year":"2020","unstructured":"McEvoy AM, Poplack S, Nickel K, et al: Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound. Breast Cancer Res Treat 183:251-262, 2020","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_9_130_2","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper LE","year":"2015","unstructured":"Schnipper LE, Davidson NE, Wollins DS, et al: American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33:2563-2577, 2015","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_131_2","doi-asserted-by":"crossref","first-page":"46s","DOI":"10.1200\/JOP.2011.000316","article-title":"Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions","volume":"7","author":"Streeter SB","year":"2011","unstructured":"Streeter SB, Schwartzberg L, Husain N, et al: Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 7:46s-51s, 2011","journal-title":"J Oncol Pract"},{"key":"e_1_3_9_132_2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina SB","year":"2014","unstructured":"Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_133_2","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1200\/JCO.2009.23.1183","article-title":"American Society of Clinical Oncology guidance statement: The cost of cancer care","volume":"27","author":"Meropol NJ","year":"2009","unstructured":"Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_134_2","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jval.2020.08.002","article-title":"Patient-provider discussion about cancer treatment costs and out-of-pocket spending: Implications for shared decision making in cancer care","volume":"23","author":"Hong YR","year":"2020","unstructured":"Hong YR, Salloum RG, Yadav S, et al: Patient-provider discussion about cancer treatment costs and out-of-pocket spending: Implications for shared decision making in cancer care. Value Health 23:1592-1598, 2020","journal-title":"Value Health"},{"key":"e_1_3_9_135_2","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2008.16.3725","article-title":"Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: Objective measurements","volume":"26","author":"McLaughlin SA","year":"2008","unstructured":"McLaughlin SA, Wright MJ, Morris KT, et al: Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: Objective measurements. J Clin Oncol 26:5213-5219, 2008","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_136_2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","article-title":"Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis","volume":"14","author":"DiSipio T","year":"2013","unstructured":"DiSipio T, Rye S, Newman B, et al: Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis. Lancet Oncol 14:500-515, 2013","journal-title":"Lancet Oncol"},{"key":"e_1_3_9_137_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.soc.2023.05.008","article-title":"Incorporating value-based decisions in breast cancer treatment algorithms","volume":"32","author":"Wang T","year":"2023","unstructured":"Wang T, Dossett LA: Incorporating value-based decisions in breast cancer treatment algorithms. Surg Oncol Clin N Am 32:777-797, 2023","journal-title":"Surg Oncol Clin N Am"},{"key":"e_1_3_9_138_2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby SC","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987-998, 2013","journal-title":"N Engl J Med"},{"key":"e_1_3_9_139_2","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.20.01703","article-title":"Toward improving patients' experiences of acute toxicity from breast radiotherapy: Insights from the analysis of patient-reported outcomes in a large multicenter cohort","volume":"38","author":"Jagsi R","year":"2020","unstructured":"Jagsi R, Griffith KA, Vicini F, et al: Toward improving patients' experiences of acute toxicity from breast radiotherapy: Insights from the analysis of patient-reported outcomes in a large multicenter cohort. J Clin Oncol 38:4019-4029, 2020","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_140_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3322\/caac.21689","article-title":"Radiation therapy-associated toxicity: Etiology, management, and prevention","volume":"71","author":"Wang K","year":"2021","unstructured":"Wang K, Tepper JE: Radiation therapy-associated toxicity: Etiology, management, and prevention. CA Cancer J Clin 71:437-454, 2021","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_9_141_2","doi-asserted-by":"crossref","first-page":"109818","DOI":"10.1016\/j.radonc.2023.109818","article-title":"Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial","volume":"187","author":"Le Bras A","year":"2023","unstructured":"Le Bras A, Belkacemi Y, Bourgier C, et al: Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial. Radiother Oncol 187:109818, 2023","journal-title":"Radiother Oncol"},{"key":"e_1_3_9_142_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ijrobp.2018.09.021","article-title":"Cost and cost-effectiveness of image guided partial breast irradiation in comparison to hypofractionated whole breast irradiation","volume":"103","author":"Shah C","year":"2019","unstructured":"Shah C, Ward MC, Tendulkar RD, et al: Cost and cost-effectiveness of image guided partial breast irradiation in comparison to hypofractionated whole breast irradiation. Int J Radiat Oncol Biol Phys 103:397-402, 2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_9_143_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-013-2412-6","article-title":"Cost-efficacy of acceleration partial-breast irradiation compared with whole-breast irradiation","volume":"138","author":"Shah C","year":"2013","unstructured":"Shah C, Lanni TB, Saini H, et al: Cost-efficacy of acceleration partial-breast irradiation compared with whole-breast irradiation. Breast Cancer Res Treat 138:127-135, 2013","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_9_144_2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ijrobp.2008.08.015","article-title":"Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: A cost-effectiveness analysis","volume":"74","author":"Sher DJ","year":"2009","unstructured":"Sher DJ, Wittenberg E, Suh WW, et al: Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: A cost-effectiveness analysis. Int J Radiat Oncol Biol Phys 74:440-446, 2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_9_145_2","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1200\/JCO.2016.72.0441","article-title":"American Society of Clinical Oncology position statement: Strategies for reducing cancer health disparities among sexual and gender minority populations","volume":"35","author":"Griggs J","year":"2017","unstructured":"Griggs J, Maingi S, Blinder V, et al: American Society of Clinical Oncology position statement: Strategies for reducing cancer health disparities among sexual and gender minority populations. J Clin Oncol 35:2203-2208, 2017","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_146_2","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.pec.2021.03.007","article-title":"I'm not putting on that floral gown: Enforcement and resistance of gender expectations for transgender people with cancer","volume":"104","author":"Alpert AB","year":"2021","unstructured":"Alpert AB, Gampa V, Lytle MC, et al: I'm not putting on that floral gown: Enforcement and resistance of gender expectations for transgender people with cancer. Patient Educ Couns 104:2552-2558, 2021","journal-title":"Patient Educ Couns"},{"key":"e_1_3_9_147_2","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: Systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Schunemann HJ","year":"2014","unstructured":"Schunemann HJ, Wiercioch W, Etxeandia I, et al: Guidelines 2.0: Systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ 186:E123-E142, 2014","journal-title":"CMAJ"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T17:59:47Z","timestamp":1746640787000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":146,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,5,10]]}},"alternative-id":["10.1200\/JCO-25-00099"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00099","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"2025-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}